Investor
Sanofi
CIK 0001121404 · filed 2026-05-07 · SEC filing
13F book
$336M
Positions
9
1 new · 0 sold
Largest name
31.4%
Meiragtx Hldgs Plc
Est. mark
−$3.65M
Price effect on 8 names still held. Flow $29.2M.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Meiragtx Hldgs Plc | — | 12.2M | $105.6M | 31.4% | $8.66M | Held |
| Inhibrx Biosciences, Inc. | INBX | 1.16M | $77.8M | 23.2% | −$13.6M | Held |
| Novavax Inc | NVAX | 6.88M | $56M | 16.7% | $9.77M | Held |
| Anaptysbio, Inc | ANAB | 821.9K | $30.4M | 9.0% | −$9.46M | Held |
| Agomab Therapeutics Nv | AGMB | 2.78M | $29.2M | 8.7% | — | New |
| MapLight Therapeutics, Inc. | MPLT | 912K | $18.5M | 5.5% | $2.52M | Held |
| Immuneering Corp | IMRX | 2.71M | $14.3M | 4.2% | −$3.55M | Held |
| Eledon Pharmaceuticals, Inc. | ELDN | 815K | $2.51M | 0.7% | $1.28M | Held |
| Q32 Bio Inc. | QTTB | 244.1K | $1.57M | 0.5% | $756.7K | Held |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.